Drugs / Tranilast
Trials 14 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 04 trials | ||||||
| Phase 0 | NCT06689514 | Jan 2025 → Dec 2026 expected | benign prostatic hyperplasia | Yifeng Jing | Recruiting | No outcome recorded |
| Phase 0 | NCT03512873 | Jun 2018 → Jun 2020 | scleredema adultorum | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| Phase 0 | NCT03528070 | May 2018 → May 2020 | sarcoidosis | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| Phase 0 | NCT03490708 | Apr 2018 → Jun 2022 | cutaneous mucinosis | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT06643689 | Jan 2025 → Dec 2027 expected | neoplasm of esophagus | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05626829 | Jul 2022 → Jul 2024 | nasopharyngeal carcinoma | Jian Guan | Unknown | No outcome recorded |
| Phase 2 | NCT03923140 | May 2019 → Apr 2024 | cryopyrin-associated periodic syndrome | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01109121 | Jun → Dec 2010 | gout | Nuon Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01052987 | Jan → Jun 2010 | gout | Nuon Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00995618 | Sep 2009 → Apr 2010 | gout | Nuon Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00882024 | Mar 2009 → Dec 2010 | rheumatoid arthritis | Nuon Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT06307288 | Oct 2023 → Jun 2024 | rosacea | Second Affiliated Hospital of Xi'an Jiaotong University | Unknown | No outcome recorded |
| Phase 4 | NCT05130892 | Nov 2021 → Feb 2023 | — | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Completed | No outcome recorded |
| Phase 4 | NCT00818805 | Jul 2008 | conjunctivitis | Alcon Research | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00717808 Comparator | Sep 2008 → Sep 2009 | rheumatoid arthritis | Imperial College London | Withdrawn | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01003613 Comparator | Feb 2009 → Jul 2011 | pterygium | Gildasio Castello de Almeida Junior | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tranilast | “Tranilast 300 mg QD; Allopurinol 400 mg QD” NCT01109121 ↗ |
| Known as | MK-341 | ChEMBL registry synonym — accepted as the source's own label CHEMBL415324 ↗ |
| Known as | NSC-758970 | ChEMBL registry synonym — accepted as the source's own label CHEMBL415324 ↗ |
| Known as | Rizaben | ChEMBL registry synonym — accepted as the source's own label CHEMBL415324 ↗ |
| Known as | Rizaben (Tranilast) | “Rizaben (Tranilast)” NCT00717808 ↗ |
| Action | Inhibit | “This drug also reduces TGF-β1 production and collagen synthesis in various cells.” NCT01003613 ↗ |
| Modality | Small molecule | — CHEMBL415324 ↗ |
| Route | Oral | “one such candidate oral treatment, tranilast” NCT00717808 ↗ |
| Target | TGFB1 | “This drug also reduces TGF-β1 production and collagen synthesis in various cells.” NCT01003613 ↗ |